长春瑞滨与顺铂治疗转移性乳腺癌

Vinorelbine and cisplatin in the treatment of metastatic breast cancers

目的：评价长春瑞滨联合顺铂（NP方案）治疗以前曾接受含阿霉素和多西紫杉醇治疗的转移性乳腺癌的疗效。方法：顺铂（75 mg/m2第1天）和长春瑞宾（25 mg/m2第1、8天）,3周/次。2周期后评价疗效,化疗3~6周期。结果：CR5例（17.9%）,PR10例（35.7%）,SD7例（25%）,PD6例（21.4%）,总有效率（CR＋PR）为53.6%。毒性反应主要为骨髓抑制、胃肠道反应。结论：顺铂/长春瑞滨方案对蒽环类和多西紫杉醇治疗失败的病人耐受性好且疗效较好。

Objective：To evaluate vinorelbine combined with cisplatin（NP） program who have received prior treatment with doxorubicin and docetaxel in metastatic breast cancer treatment efficacy.Methods：Cisplatin（75 mg/m2 day 1） and vinorelbine（25 mg/m2 days 1 and 8） were administered every 3 weeks.The median age was 51yr（41-69）.A total of 115 cycles of chemotherapy was given,with a median of 4 cycles（3-6）.Results： Five patients achieved a complete response（17.9%）,and ten patients achieved a partial response（35.7%）,with an overall response rate of 53.6%.Stable disease was observed in seven patients（25%）,six patients had progressive disease（21.4%）.The main toxicity of this group of mainly bone marrow suppression,gastrointestinal tract reaction.Conclusion：This cisplatin/vinorelbine regimen is well tolerated and active in patients who failed anthracyclines and docetaxel treatment.